DOP2025000179A - Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4' - Google Patents

Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'

Info

Publication number
DOP2025000179A
DOP2025000179A DO2025000179A DO2025000179A DOP2025000179A DO P2025000179 A DOP2025000179 A DO P2025000179A DO 2025000179 A DO2025000179 A DO 2025000179A DO 2025000179 A DO2025000179 A DO 2025000179A DO P2025000179 A DOP2025000179 A DO P2025000179A
Authority
DO
Dominican Republic
Prior art keywords
reverse transcriptase
prodrugs
nucleoside reverse
transcriptase inhibitors
substituted nucleoside
Prior art date
Application number
DO2025000179A
Other languages
English (en)
Inventor
E Layton Mark
T Raheem Izzat
W Embrey Mark
A Grobler Jay
Original Assignee
Merck Sharp & Dohme Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme Llc filed Critical Merck Sharp & Dohme Llc
Publication of DOP2025000179A publication Critical patent/DOP2025000179A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • AIDS & HIV (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a profármacos del compuesto A: que son inhibidores nucleosídicos de la translocación de la transcriptasa inversa (NRTTI) y son útiles en la inhibición de la transcriptasa inversa del VIH. La presente invención también se refiere al uso de estos compuestos para la profilaxis de la infección por VIH, el tratamiento de la infección por VIH y la profilaxis, el tratamiento y el retraso del inicio o la progresión del SIDA y/o complejos relacionados con el SIDA.
DO2025000179A 2023-01-30 2025-07-24 Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4' DOP2025000179A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202363482133P 2023-01-30 2023-01-30
US202363607595P 2023-12-08 2023-12-08
PCT/US2024/013021 WO2024163262A2 (en) 2023-01-30 2024-01-26 Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors

Publications (1)

Publication Number Publication Date
DOP2025000179A true DOP2025000179A (es) 2025-09-15

Family

ID=90362074

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2025000179A DOP2025000179A (es) 2023-01-30 2025-07-24 Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'

Country Status (17)

Country Link
US (1) US20240287124A1 (es)
EP (1) EP4658663A2 (es)
JP (1) JP2025541056A (es)
KR (1) KR20250140092A (es)
CN (1) CN120958007A (es)
AU (1) AU2024213822A1 (es)
CL (1) CL2025002243A1 (es)
CO (1) CO2025010224A2 (es)
CR (1) CR20250310A (es)
DO (1) DOP2025000179A (es)
GE (1) GEAP202516835A (es)
IL (1) IL322370A (es)
JO (1) JOP20250193A1 (es)
MX (1) MX2025008847A (es)
PE (1) PE20252245A1 (es)
TW (1) TW202434594A (es)
WO (1) WO2024163262A2 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
CN119462611A (zh) 2016-08-19 2025-02-18 吉利德科学公司 用于预防性或治疗性治疗hiv病毒感染的治疗性化合物
US20190185508A1 (en) * 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
JP2021536444A (ja) 2018-08-30 2021-12-27 グラクソスミスクライン、インテレクチュアル、プロパティー、(ナンバー2)、リミテッドGlaxosmithkline Intellectual Property (No.2) Limited Ｈｉｖ療法に有用な化合物
CN113811360A (zh) * 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
CA3146679A1 (en) * 2019-07-27 2021-02-04 Brii Biosciences, Inc. Adenosine derivative and pharmaceutical composition comprising the same
WO2021188959A1 (en) * 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
EP4281081A4 (en) * 2021-01-25 2025-05-14 Brii Biosciences, Inc. ADENOSINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION THEREOF

Also Published As

Publication number Publication date
PE20252245A1 (es) 2025-09-15
KR20250140092A (ko) 2025-09-24
WO2024163262A3 (en) 2024-10-10
MX2025008847A (es) 2025-09-02
CR20250310A (es) 2025-08-25
CN120958007A (zh) 2025-11-14
US20240287124A1 (en) 2024-08-29
TW202434594A (zh) 2024-09-01
JOP20250193A1 (ar) 2025-07-29
CO2025010224A2 (es) 2025-08-19
EP4658663A2 (en) 2025-12-10
AU2024213822A1 (en) 2025-08-07
JP2025541056A (ja) 2025-12-18
IL322370A (en) 2025-09-01
WO2024163262A2 (en) 2024-08-08
CL2025002243A1 (es) 2025-11-03
GEAP202516835A (en) 2025-11-25

Similar Documents

Publication Publication Date Title
AR130699A2 (es) Inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
AR052034A1 (es) Sal potasica de un inhibidor de la integrasa de vih
MX2019007585A (es) Profarmacos de ester alifatico antiviricos de tenofovir.
NI200900103A (es) Inhibidores de transcriptasa inversa no nucleosídicos
PE20221036A1 (es) Profarmacos antivirales y formulaciones de los mismos
MX2018003212A (es) Inhibidores de transcriptasa inversa de nucleosido 4'-substituido y preparaciones de los mismos.
NI201800083A (es) Procedimiento para el tratamiento y la profilaxis de vih y sida
PA8608901A1 (es) Derivados de piperazina
CR20120503A (es) Inhibidores no nucleosídicos de la transcriptasa inversa
CL2022000659A1 (es) Derivados de pirimidona como agentes citotóxicos selectivos contra células infectadas por vih. (divisional de solicitud 202101514)
MX2021007544A (es) Nuevas formas cristalinas de un compuesto inhibidor de la translocacion de la transcriptasa inversa de nucleosidos.
CL2021001117A1 (es) Nuevas 6,7-dihidro-4h-pirazolo[1,5-a] pirazinindol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
MX2023008004A (es) Derivado de adenosina y composicion farmaceutica que lo comprende.
CL2024002371A1 (es) Compuestos con estructura en t formada por al menos cuatro ciclos para tratamiento del cáncer
CO2025010224A2 (es) Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4'
AR131704A1 (es) Profármacos de inhibidores de la transcriptasa inversa de nucleósidos sustituidos en 4’
UY39172A (es) Análogos de nucleósido bi- y monocíclicos para el tratamiento de la hepatitis e
CU20220045A7 (es) Compuestos derivados sustituidos de pirimidina para el tratamiento y prevención de la infección por vih
MX2021013634A (es) Composiciones estables de albuvirtida.
WO2021202990A3 (en) Methods for the treatment of betacoronavirus infections
AR133187A1 (es) Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos
AR123347A1 (es) Derivados de tetrahidroquinazolina como agentes citotóxicos selectivos
BR112022020810A2 (pt) Análogos de nucleosídeos espirocíclicos para o tratamento de hepatite e
MX2022012901A (es) Análogos de nucleósido de alquinilo para el tratamiento de la hepatitis e.
AR107596A1 (es) Procedimientos para el tratamiento y la profilaxis de vih y sida